Photo credit: jarmoluk / pixabay.com
Russian scientists have developed the medicine levilimab, which is highly effective for the severe form of coronavirus infection, RIA Novosti reports. It is reported to prevent cytokine storms - a complication that most often leads to death.
The results of the Phase III clinical trial are published in the Inflammation Research journal.
Levilimab is a original inhibitor of Interleukin 6 receptor. It is developed by BIOCAD - the Russian biotechnology company.
For patients diagnosed with COVID-19 without signs of another infection and not requiring mechanical ventilation, the use of levilimab along with standard treatment led to an increase in the rate of sustained clinical improvement.
The study involved 217 patients - men and non-pregnant women aged 18 years and older, hospitalized for severe COVID-19 pneumonia. 63.1% and 42.7% of patients in the levilimab and in the placebo groups, respectively, achieved sustained clinical improvement on Day 14.
The number of research centers in Russia where the studies were carried out exceeded ten in accordance with the Declaration of Helsinki and the standards of good clinical practice.
Russkiy Mir
